|
Published by: GBI Research
Published: Nov. 1, 2012 - 59 Pages
Table of Contents
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Downstream Processing in Biopharmaceuticals - Introduction
- 3 Downstream Processing in Biopharmaceuticals - Market Overview
- 3.1 Overview of Biopharmaceuticals
- 3.1.1 Cytokines
- 3.1.2 Enzymes
- 3.1.3 Hormones
- 3.1.4 Clotting Factors
- 3.1.5 Vaccines
- 3.1.6 Monoclonal Antibodies
- 3.1.7 Cell Therapies
- 3.1.8 Antisense Drugs
- 3.1.9 Peptide Therapeutics
- 3.2 Overview of Downstream Processing in Biopharmaceuticals
- 3.2.1 A Typical Downstream Processing Operation
- 3.2.2 Major Check Points during Downstream Processing
- 4 Downstream Processing in Biopharmaceuticals - Role of Downstream Processing in the Biopharmaceutical Industry
- 4.1 Major Reagents, Reagent Suppliers and Reagents Market related to Downstream Process
- 4.1.1 Major Reagents
- 4.1.2 Reagent Suppliers
- 4.1.3 Reagent Market
- 4.2 Major Equipment Suppliers
- 5 Downstream Processing in Biopharmaceuticals - Downstream Processing Market for CMOs
- 5.1 Global CMO Market Overview
- 5.2 CMO Biopharmaceuticals Market Characterization
- 5.3 CMO Market Size for Downstream Processing
- 6 Downstream Processing in Biopharmaceuticals - Challenges and Unmet Needs in Downstream Bioprocess
- 6.1 Challenges
- 6.1.1 Chromatographic Capture
- 6.1.2 Reducing the Purification Steps
- 6.1.3 Titer Increment/Capacity Bottleneck
- 6.1.4 Virus Clearances
- 6.1.5 Scaling –Up
- 6.2 Unmet Needs
- 6.2.1 Unmet Medical Needs
- 6.2.2 Realistic Achievement of Economies of Scale
- 6.2.3 Technological Development of Disposables at Large Scale
- 6.2.4 Reagent Costs and their Effectiveness
- 7 Downstream Processing in Biopharmaceuticals - Emerging Technologies and their Implications
- 7.1 Single Use Technology/Disposable Technology
- 7.1.1 Advantages
- 7.1.2 Disadvantages
- 7.2 Multi-column Chromatography
- 7.2.1 Advantages
- 7.2.2 Disadvantages
- 7.3 Tangential Flow Filtration
- 7.3.1 Advantages
- 7.3.2 Disadvantages
- 8 Downstream Processing in Biopharmaceuticals - Industry Analysis
- 8.1 Key Drivers and Restraints
- 8.1.1 Key Drivers of Downstream Processing Market
- 8.1.2 Key Restraints of Downstream Processing Market
- 8.2 Porter’s Five Forces Model for Industry Analysis
- 8.3 Major Events and their Impact – Analysis
- 9 Downstream Processing in Biopharmaceuticals - Competitive Landscape
- 9.1 Market Dynamics of Downstream Processing and Impact
- 9.1.1 Market Structure
- 9.2 Key Equipment Players
- 9.2.1 Pall Corporation
- 9.2.2 Millipore
- 9.2.3 Sartorius Stedim Biotech S.A.
- 9.3 Key Reagent Players
- 9.3.1 Life Technologies
- 9.3.2 Sigma Aldrich
- 9.4 Key CMO Players
- 9.4.1 Lonza
- 9.4.2 Boehringer Ingelheim
- 9.4.3 Diosynth Biotechnology
- 10 Downstream Processing in Biopharmaceuticals - Appendix
- 10.1 Market Definitions
- 10.2 Abbreviations
- 10.3 Bibliography
- 10.4 Research Methodology
- 10.4.1 Coverage
- 10.4.2 Secondary Research
- 10.4.3 Primary Research
- 10.4.4 Expert Panel Validation
- 10.5 Contact Us
- 10.6 Disclaimer
- 1.1 List of Tables
- Table 1: Downstream Processing, Global, Cost Breakups of Upstream and Downstream Processing, 2011
- Table 2: Downstream Processing, Global, Reagent Suppliers, 2011
- Table 3: Downstream Processing, Global, Total Reagent Market for Downstream Processing, Revenue ($m), 2009–2011
- Table 4: Downstream Processing, Global, Total Reagent Market for Downstream Processing, Revenue Forecast ($m), 2011–2018
- Table 5: Downstream Processing, Global, Equipment Suppliers, 2011
- Table 6: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue ($bn), 2008–2011
- Table 7: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue Forecast ($bn), 2011–2018
- Table 8: Downstream Processing, Global, Downstream Processing Market for CMOs, Revenue ($bn), 2009–2011
- Table 9: Downstream Processing, Global, Downstream Processing Market for CMOs, Revenue ($bn), 2011–2018
- Table 10: Downstream Processing, Key Equipment Players, Pall Corporation, Major M&A Deals, 2009–2012
- Table 11: Downstream Processing, Key Equipment Players, EMD Millipore, Major M&A Deals, 2009–2010
- Table 12: Downstream Processing, Key Equipment Players, Sartorius Stedim Biotech S.A, Major M&A Deals, 2008
- Table 13: Downstream Processing, Key Reagent Players, Life Technologies, Major M&A Deals, 2009–2011
- Table 14: Downstream Processing, Key Reagent Players, Sigma-Aldrich, Major M&A Deals, 2009–2012
- Table 15: Downstream Processing, Key CMO Players, Lonza, Major M&A Deals, 2009–2010
- Table 16: Downstream Processing, Key CMO Players, Boehringer Ingelhiem, Major M&A Deals, 2009–2011
- Table 17: Downstream Processing, Key CMO Players, Diosynth Biotechnology, Major M&A Deals, 2009–2011
- 1.2 List of Figures
- Figure 1: Downstream Processing, Global, Biopharmaceutical Types, 2011
- Figure 2: Downstream Processing, Global, Overview of General Drug Development Process, 2011
- Figure 3: Downstream Processing, Global, Process Steps, 2011
- Figure 4: Downstream Processing, Global, Changing Distribution of Cost along with Yield Increment, 2011
- Figure 5: Downstream Processing, Global, Yield Percentage vs Number of Purification Steps, 2011
- Figure 6: Downstream Processing, Global, Cost Breakups of Upstream and Downstream Processing, 2011
- Figure 7: Downstream Processing, Global, Total Reagent Market for Downstream Processing, Revenue ($m), 2009–2018
- Figure 8: Downstream Processing, Global, CMO Biopharmaceutical Market, Revenue ($bn), 2008–2018
- Figure 9: Downstream Processing, Global, Downstream Processing Market for CMOs, Revenue ($bn), 2009–2018
- Figure 10: Downstream Processing, Global, Challenges, 2011
- Figure 11: Downstream Processing, Global, Emerging Technologies and their Likely Adaptation, 2011
- Figure 12: Downstream Processing, Global, Industry Analysis, Key Drivers and Restraints, 2011
- Figure 13: Downstream Processing, Global, Industry Analysis, Porter’s Five Forces Model, 2011
- Figure 14: Downstream Processing, Global, Industry Analysis, Major Market Events and their Impact, 2011
- Figure 15: Downstream Processing, Global, Industry Analysis, Market Dynamics, 2011
- Figure 16: Downstream Processing, Key Equipment Players, Business Overview, Pall Corporation, 2011
- Figure 17: Downstream Processing, Key Equipment Players, Business Overview, EMD Millipore, 2011
- Figure 18: Downstream Processing, Key Equipment Players, Business Overview, Sartorius Stedim Biotech S.A, 2011
- Figure 19: Downstream Processing, Key Reagent Players, Business Overview, Life Technologies, 2011
- Figure 20: Downstream Processing, Key Reagent Players, Business Overview, Sigma-Aldrich, 2011
- Figure 21: Downstream Processing, Key CMO Players, Business Overview, Lonza, 2011
- Figure 22: Downstream Processing, Key CMO Players, Business Overview, Boehringer Ingelheim, 2011
- Figure 23: Downstream Processing, Key CMO Players, Business Overview, Diosynth Biotechnology, 2011
AbstractDownstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness
Summary
GBI Research, the leading business intelligence provider, has released its latest research, “Downstream Processing in Biopharmaceuticals - Adoption of Disposable Technology at Improved Economies of Scale to Optimize Production Efficiency and Cost-effectiveness”, which provides key data, information and analysis of the Contract Manufacturing Organization (CMO) industry, and the downstream processing and reagent market. The report provides comprehensive insight into the size of the CMO market, the downstream processing and reagent market and includes forecasts, key reasons for outsourcing, market characterization, downstream process in biopharmaceuticals, major reagents, reagent suppliers and the reagent market related to downstream processing, profiles of key equipment players, key reagent players and key CMO players, drivers and restraints and deals analysis.
This report is built using data and information sourced from proprietary databases, primary and secondary research and uses in-house analysis from GBI Research’s team of industry experts.
Major CMOs offer both upstream and downstream manufacturing functions equally. In addition to manufacturing in biopharmaceutical production, they also offer clinical trials, logistics, packaging, and even marketing. According to industry experts, almost 60% of the CMO market in dominated by manufacturing functions, out of which more than 50% is dominated by the downstream process. GBI research suggests that the CMO market size for downstream processing is set to grow at a Compound Annual Growth Rate (CAGR) of 15.1%, which is more than the growth in the overall CMO biopharmaceutical market.
Scope- A detailed overview of the downstream processing, CMO industry and reagent market.
- Annualized market data and forecasts for the downstream processing, CMO industry and reagent market.
- A detailed overview of key reasons behind outsourcing, outsourcing service models and key drivers and restraints of the market.
- A detailed discussion of the downstream processing.
- Company profiles of major equipments suppliers, CMOs and reagent players including the key services offered by them and their financial information.
- Analysis of the Merger and Acquisition (M&A) deals involving key companies
Reasons to buy- Develop market-entry and market expansion strategies by identifying areas for high growth and opportunities.
- Understand the factors shaping the downstream processing, CMO industry and reagent market.
- Identify the top players in the major equipment suppliers, CMO and reagent market, their financial revenues, geographical presence and key services offered.
- Analyze the key geographies that are lucrative markets for the downstream processing and as well as CMOs.
- Analyze the trends in licensing and M&A deals and explore potential investment opportunities
- Understand upcoming trends that are poised to drive the future growth of the downstream processing
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
